ICMR Profile picture
Aug 1 12 tweets 19 min read
1/n) ICMR released Standard Treatment Workflows (STWs) volume 3 which contains 11 specialties with 52 diseases. It is accessible at stw.icmr.org.in/stws and on the Mobile App.
@MoHFW_INDIA @DeptHealthRes #STW
2/n) Standard Treatment Workflows (STWs) on #𝐃𝐞𝐫𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲 containing 14 major diseases. It is accessible at stw.icmr.org.in/stws and on the Mobile App. @MoHFW_INDIA @DeptHealthRes
3/n) Standard Treatment Workflows (STWs) on #Endocrinology containing 06 major diseases. It is accessible at stw.icmr.org.in/stws and on the Mobile App. @MoHFW_INDIA @AyushmanNHA @WHOSEARO #diabetes
4/n) Standard Treatment Workflows (STWs) on #Gastroenterology containing 04 major diseases. It is accessible at stw.icmr.org.in/stws and on the Mobile App. @MoHFW_INDIA @AyushmanNHA @WHOSEARO
5/n) Standard Treatment Workflows (STWs) on #GeneralSurgery containing 05 major diseases. It is accessible at stw.icmr.org.in/stws and on the Mobile App. @MoHFW_INDIA @AyushmanNHA @WHOSEARO
6/n) Standard Treatment Workflow (STW) on #HaemolyticAnaemia containing 01 disease. It is accessible at stw.icmr.org.in/stws and on the Mobile App. @MoHFW_INDIA @AyushmanNHA @WHOSEARO @PIB_India
7/n) Standard Treatment Workflow (STW) on #Infertility containing 01 disease. It is accessible at stw.icmr.org.in/stws and on the Mobile App. @MoHFW_INDIA @AyushmanNHA @WHOSEARO @PIB_India @PIB_India
8/n) Standard Treatment Workflows (STWs) on Naeonatology containing 08 diseases. It is accessible at stw.icmr.org.in/stws and on the Mobile App. @MoHFW_INDIA @AyushmanNHA @WHOSEARO @DeptHealthRes @PIB_India
9/n) Standard Treatment Workflows (STWs) on #Oncology containing 03 diseases. It is accessible at stw.icmr.org.in/stws and on the Mobile App. @MoHFW_INDIA @AyushmanNHA @WHOSEARO @DeptHealthRes @PIB_India #breastcancer #lungcancer #oralcancer
10/n) Standard Treatment Workflows (STWs) on #Ophthalmology containing 03 diseases. It is accessible at stw.icmr.org.in/stws and on the Mobile App. @MoHFW_INDIA @AyushmanNHA @WHOSEARO @DeptHealthRes @PIB_India
11/n) Standard Treatment Workflows (STWs) on #Orthopaedics containing 02 diseases. It is accessible at stw.icmr.org.in/stws and on the Mobile App. @MoHFW_INDIA @DeptHealthRes @AyushmanNHA @WHOSEARO @PIB_India @NMC_IND
n/n) Standard Treatment Workflows (STWs) on #Paediatric #Surgery containing 05 diseases. It is accessible at stw.icmr.org.in/stws and on the Mobile App. @MoHFW_INDIA @DeptHealthRes @AyushmanNHA @WHOSEARO @PIB_India @NMC_IND

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with ICMR

ICMR Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ICMRDELHI

Dec 22, 2020
India State-Level Disease Burden Initiative Air Pollution Collaborators. Health and economic impact of air pollution in the states of India: the Global Burden of Disease Study 2019. Lancet Planetary Health. 22 December 2020.
thelancet.com/journals/lanpl…
1.67 million deaths were attributable to air pollution in India in 2019, 17.8% of the total deaths in the country, the majority of which were from outdoor particulate air pollution (0·98 million) and household air pollution (0·61 million) Read more in thelancet.com/journals/lanpl…
Household air pollution is decreasing in India resulting in 64% reduction in the death rate attributable to it from 1990 to 2019, whereas the death rate from outdoor particulate air pollution has increased during this period by 115%. Read more in thelancet.com/journals/lanpl…
Read 6 tweets
Apr 28, 2020
Currently, there are no approved, definitive therapies for #COVID19. Convalescent plasma is one of the several emerging therapies. However, there is no robust evidence to support it for routine therapy. @US_FDA has also viewed it as an experimental therapy (IND). 1/4
#COVID19 convalescent plasma therapy comes with its own share of technical challenges, like antibody titer testing. There are also several risks of using this therapy including life-threatening allergic reactions and lung injury. 2/4
Given the serious uncertainties around #COVID19 convalescent plasma therapy, @ICMRDelhi has initiated a multi-center clinical trial to evaluate the safety and efficacy of using this therapy in #COVID19 patients in India. 3/4
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(